These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 22526901)

  • 1. FANCJ expression predicts the response to 5-fluorouracil-based chemotherapy in MLH1-proficient colorectal cancer.
    Nakanishi R; Kitao H; Fujinaka Y; Yamashita N; Iimori M; Tokunaga E; Yamashita N; Morita M; Kakeji Y; Maehara Y
    Ann Surg Oncol; 2012 Oct; 19(11):3627-35. PubMed ID: 22526901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mismatch repair protein expression is an independent prognostic factor in sporadic colorectal cancer.
    Ohrling K; Edler D; Hallström M; Ragnhammar P
    Acta Oncol; 2010 Aug; 49(6):797-804. PubMed ID: 20307245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of the hMLH1 gene is a possible predictor for the clinical response to 5-fluorouracil after a surgical resection in colorectal cancer.
    Ide T; Kitajima Y; Ohtaka K; Mitsuno M; Nakafusa Y; Miyazaki K
    Oncol Rep; 2008 Jun; 19(6):1571-6. PubMed ID: 18497967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the link between BACH1/FANCJ and MLH1 in DNA crosslink repair.
    Cantor SB; Xie J
    Environ Mol Mutagen; 2010 Jul; 51(6):500-7. PubMed ID: 20658644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The FANCJ/MutLalpha interaction is required for correction of the cross-link response in FA-J cells.
    Peng M; Litman R; Xie J; Sharma S; Brosh RM; Cantor SB
    EMBO J; 2007 Jul; 26(13):3238-49. PubMed ID: 17581638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An MLH1 mutation links BACH1/FANCJ to colon cancer, signaling, and insight toward directed therapy.
    Xie J; Guillemette S; Peng M; Gilbert C; Buermeyer A; Cantor SB
    Cancer Prev Res (Phila); 2010 Nov; 3(11):1409-16. PubMed ID: 20978114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thymidylate synthase and microsatellite instability in colorectal cancer: implications for disease free survival, treatment response and survival with metastases.
    Bendardaf R; Lamlum H; Ristamäki R; Korkeila E; Syrjänen K; Pyrhönen S
    Acta Oncol; 2008; 47(6):1046-53. PubMed ID: 17943475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Microsatellite instability. A new predictive marker (?)].
    Dietmaier W
    Pathologe; 2010 Oct; 31 Suppl 2():268-73. PubMed ID: 20824433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical detection of ARID1A in colorectal carcinoma: loss of staining is associated with sporadic microsatellite unstable tumors with medullary histology and high TNM stage.
    Ye J; Zhou Y; Weiser MR; Gönen M; Zhang L; Samdani T; Bacares R; DeLair D; Ivelja S; Vakiani E; Klimstra DS; Soslow RA; Shia J
    Hum Pathol; 2014 Dec; 45(12):2430-6. PubMed ID: 25311944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer.
    Jover R; Zapater P; Castells A; Llor X; Andreu M; Cubiella J; Piñol V; Xicola RM; Bujanda L; Reñé JM; Clofent J; Bessa X; Morillas JD; Nicolás-Pérez D; Payá A; Alenda C;
    Gut; 2006 Jun; 55(6):848-55. PubMed ID: 16299036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nuclear orphan receptor NR4A2 confers chemoresistance and predicts unfavorable prognosis of colorectal carcinoma patients who received postoperative chemotherapy.
    Han Y; Cai H; Ma L; Ding Y; Tan X; Liu Y; Su T; Yu Y; Chang W; Zhang H; Fu C; Cao G
    Eur J Cancer; 2013 Nov; 49(16):3420-30. PubMed ID: 23809767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.
    Sinicrope FA; Foster NR; Thibodeau SN; Marsoni S; Monges G; Labianca R; Kim GP; Yothers G; Allegra C; Moore MJ; Gallinger S; Sargent DJ
    J Natl Cancer Inst; 2011 Jun; 103(11):863-75. PubMed ID: 21597022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crosstalk between BRCA-Fanconi anemia and mismatch repair pathways prevents MSH2-dependent aberrant DNA damage responses.
    Peng M; Xie J; Ucher A; Stavnezer J; Cantor SB
    EMBO J; 2014 Aug; 33(15):1698-712. PubMed ID: 24966277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-10b is a prognostic indicator in colorectal cancer and confers resistance to the chemotherapeutic agent 5-fluorouracil in colorectal cancer cells.
    Nishida N; Yamashita S; Mimori K; Sudo T; Tanaka F; Shibata K; Yamamoto H; Ishii H; Doki Y; Mori M
    Ann Surg Oncol; 2012 Sep; 19(9):3065-71. PubMed ID: 22322955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microsatellite instability testing and its role in the management of colorectal cancer.
    Kawakami H; Zaanan A; Sinicrope FA
    Curr Treat Options Oncol; 2015 Jul; 16(7):30. PubMed ID: 26031544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
    Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
    JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathologic features of synchronous colorectal carcinoma: A distinct subset arising from multiple sessile serrated adenomas and associated with high levels of microsatellite instability and favorable prognosis.
    Hu H; Chang DT; Nikiforova MN; Kuan SF; Pai RK
    Am J Surg Pathol; 2013 Nov; 37(11):1660-70. PubMed ID: 23887157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines.
    Arnold CN; Goel A; Boland CR
    Int J Cancer; 2003 Aug; 106(1):66-73. PubMed ID: 12794758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lysosomal acid phosphatase 2 is an unfavorable prognostic factor but is associated with better survival in stage II colorectal cancer patients receiving chemotherapy.
    Lee YC; Su CY; Lin YF; Lin CM; Fang CY; Lin YK; Hsiao M; Chen CL
    Oncotarget; 2017 Feb; 8(7):12120-12132. PubMed ID: 28076332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients.
    Lanza G; Gafà R; Santini A; Maestri I; Guerzoni L; Cavazzini L
    J Clin Oncol; 2006 May; 24(15):2359-67. PubMed ID: 16710035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.